Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

Canagliflozin is a sodium glucose co‐transporter 2 inhibitor in development for type 2 diabetes mellitus (T2DM). The efficacy and safety of canagliflozin were evaluated in subjects with T2DM inadequately controlled with diet and exercise.

[1]  L. Morrow,et al.  Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. , 2014, Metabolism: clinical and experimental.

[2]  S. Mudaliar,et al.  Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion , 2013, Diabetes Care.

[3]  S. Inzucchi,et al.  Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2013, Diabetologia.

[4]  S. Schwartz,et al.  Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin , 2012, Diabetes, obesity & metabolism.

[5]  P. Nyirjesy,et al.  Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor , 2012, Current medical research and opinion.

[6]  J. Rosenstock,et al.  Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes , 2012, Diabetes Care.

[7]  L. Nicolle,et al.  Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study , 2012, Current medical research and opinion.

[8]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.

[9]  G. Bray,et al.  Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study , 2012, Diabetes Care.

[10]  F. Du,et al.  Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models , 2012, PloS one.

[11]  D. Wexler,et al.  Canagliflozin, a novel inhibitor of sodium glucose co‐transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects , 2011, Diabetes, obesity & metabolism.

[12]  Nisa M. Maruthur,et al.  Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations , 2011, Annals of Internal Medicine.

[13]  Y. Koga,et al.  Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. , 2010, Journal of medicinal chemistry.

[14]  E. Ferrannini,et al.  Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise , 2010, Diabetes Care.

[15]  Joshua J. Neumiller,et al.  Sodium-Glucose Co-Transport Inhibitors Progress and Therapeutic Potential in Type 2 Diabetes Mellitus , 2010 .

[16]  B. Wajchenberg.  Clinical approaches to preserve beta-cell function in diabetes. , 2010, Advances in experimental medicine and biology.

[17]  Ralph A. DeFronzo,et al.  From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus , 2009, Diabetes.

[18]  E. Standl.  The importance of β‐cell management in type 2 diabetes , 2007 .

[19]  Michael Cook,et al.  Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care , 2007, Diabetic medicine : a journal of the British Diabetic Association.

[20]  E. Standl.  The importance of beta-cell management in type 2 diabetes. , 2007, International journal of clinical practice. Supplement.

[21]  R. Holman,et al.  Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. , 2005, Diabetes care.

[22]  Judith Wylie-Rosett,et al.  Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition. , 2004, Diabetes care.